+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

  • ID: 4901273
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 87 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bayer AG
  • Novartis AG
  • Pfizer Inc
  • TheraBiologics Inc
  • MORE
Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape.

Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Oligoastrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Anaplastic Oligoastrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Oligoastrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Oligoastrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Oligoastrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bayer AG
  • Novartis AG
  • Pfizer Inc
  • TheraBiologics Inc
  • MORE
Introduction
Report Coverage
Anaplastic Oligoastrocytoma - Overview
Anaplastic Oligoastrocytoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaplastic Oligoastrocytoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bayer AG
Boehringer Ingelheim International GmbH
Novartis AG
Pfizer Inc
TheraBiologics Inc
Anaplastic Oligoastrocytoma - Drug Profiles
Anaplastic Oligoastrocytoma - Dormant Projects
Anaplastic Oligoastrocytoma - Discontinued Products
Anaplastic Oligoastrocytoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by Astellas Pharma Inc, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by Bayer AG, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by Novartis AG, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by Pfizer Inc, H2 2019
Anaplastic Oligoastrocytoma - Pipeline by TheraBiologics Inc, H2 2019
Anaplastic Oligoastrocytoma - Dormant Projects, H2 2019
Anaplastic Oligoastrocytoma - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Anaplastic Oligoastrocytoma, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Astellas Pharma Inc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Pfizer Inc
  • TheraBiologics Inc
Note: Product cover images may vary from those shown
Adroll
adroll